Antibe Therapeutics Inc.
ATBPF · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.05 | 5.12 | -0.45 |
| FCF Yield | -52.55% | -42.00% | -0.06% | -7.50% |
| EV / EBITDA | -1.27 | -0.22 | -5.12 | -8.64 |
| Quality | ||||
| ROIC | -30.59% | -30.01% | -32.31% | -217.01% |
| Gross Margin | 0.00% | 0.00% | 36.55% | 38.24% |
| Cash Conversion Ratio | 0.84 | 0.68 | 0.00 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | 0.60% | 4.34% |
| Free Cash Flow Growth | 3.63% | -16,022.86% | 99.12% | -65.49% |
| Safety | ||||
| Net Debt / EBITDA | 0.35 | 1.38 | 3.12 | 0.21 |
| Interest Coverage | -2,568.25 | -3,191.13 | -3,696.94 | -37.24 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 2.75 | 2.86 | 1.74 |
| Cash Conversion Cycle | 0.00 | -8,164.74 | 29.62 | 30.10 |